预约演示
更新于：2026-01-26
Landiolol Hydrochloride
盐酸兰地洛尔
更新于：2026-01-26
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C25H40ClN3O8 |
InChIKeyDLPGJHSONYLBKP-IKGOIYPNSA-N |
CAS号144481-98-1 |
关联
80
项与 盐酸兰地洛尔 相关的临床试验CTIS2025-523676-23-00
The effect of early Landiolol in patients with ST-elevation acute coronary syndrome undergoing primary percutaneous coronary intervention – A prospective, randomized, double- blinded, placebo controlled, phase IV pilot trial (STEMILAND-1)
CTR20254435
一项评价注射用盐酸兰地洛尔用于全麻手术期心动过速性心律失常安全及有效性的多中心、随机双盲、安慰剂对照III期临床研究
ChiCTR2500113077
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of Landiolol Hydrochloride for Injection in the Management of Tachyarrhythmia During General Anesthesia Surgery
100 项与 盐酸兰地洛尔 相关的临床结果
登录后查看更多信息
100 项与 盐酸兰地洛尔 相关的转化医学
登录后查看更多信息
100 项与 盐酸兰地洛尔 相关的专利（医药）
登录后查看更多信息
439
项与 盐酸兰地洛尔 相关的文献（医药）2026-02-01COMPUTATIONAL BIOLOGY AND CHEMISTRY
Ahnak and Nckap1l as potential diagnostic biomarkers and therapeutic targets in Landiolol-mediated sepsis treatment
Article
作者: Zhu, Xingping ; Tu, Su ; Qian, Bin ; Liu, Xiaoxia ; Cui, Junli ; Pan, Weiyu
PURPOSE:
Landiolol is a beta-blocker used in the treatment of Sepsis. However, how this drug influences key genes and pathways involved in disease remains unknown. This study aimed to explore potential biomarkers involved in the mechanism of Landiolol's action in sepsis.
METHODS:
Two microarray datasets from the Gene Expression Omnibus database were downloaded. Differentially expressed genes (DEGs) were identified. Then, Landiolol-associated genes (lnd-DEGs) were screened using weighted gene co-expression network analysis (WGCNA), followed by enrichment analysis and protein-protein interaction (PPI) network investigation. Biomarkers were explored using three machine learning methods (LASSO, SVM-RFE, and RF), followed by diagnostic and prognostic analyses of these biomarkers.
RESULTS:
After landiolol treatment, a total of 45 DEGs were identified when compared to normal samples. These genes were primarily associated with 357 biological functions, including the inositol phosphate metabolic process, and six key pathways, including the phosphatidylinositol signaling system. Using three different machine learning methods, 4 signature genes related to landiolol's action on sepsis were identified. Receiver operating characteristic (ROC) analysis demonstrated high predictive accuracy for Ahnak and Nckap1l in sepsis. Clinical correlation analysis revealed that Nckap1l and Ahnak were significantly associated with endotype and overall survival (OS) of sepsis, respectively. Finally, the prognostic value of Ahnak was validated through Kaplan-Meier analysis.
CONCLUSIONS:
Ahnak and Nckap1l are potential diagnostic biomarkers and targets for therapeutic intervention in landiolol-induced sepsis following administration of Landiolol. Nckap1l can be used for endotype analysis of sepsis.
2026-02-01COMPUTATIONAL BIOLOGY AND CHEMISTRY
Corrigendum to “Ahnak and Nckap1l as potential diagnostic biomarkers and therapeutic targets in Landiolol-mediated sepsis treatment” [Comput. Biol. Chem. 120 (2026) 108700]
作者: Zhu, Xingping ; Tu, Su ; Qian, Bin ; Liu, Xiaoxia ; Cui, Junli ; Pan, Weiyu
2026-01-01BRITISH JOURNAL OF ANAESTHESIA
Low dose of landiolol does not prevent postoperative atrial fibrillation after cardiac surgery in non-Asian patients: a multicentre randomised study
Article
作者: Squara, Pierre ; Morichau-Beauchant, Tristan ; Besnard, Aurélie ; Frossard, Benjamin ; Amour, Julien ; Naudin, Cécile ; Laverdure, Florent ; Merzoug, Messaouda ; Géri, Guillaume
BACKGROUND:
Postoperative atrial fibrillation (POAF) affects 30% of patients undergoing cardiac surgery with cardiopulmonary bypass (CPB). Beta-blockers are the first-line agents recommended for POAF prevention. Landiolol, an ultra-short-acting, highly selective beta-1-blocker, has been shown to be effective in reducing POAF in Asian patients at a low dose of 2 μg kg-1 min-1. The aim of this study was to evaluate the effect of a low dose of landiolol for the prevention of POAF in non-Asian patients after cardiac surgery.
METHODS:
This multicentre, double-blind, randomised, placebo-controlled superiority trial was conducted from January 2021 to July 2023 at three hospitals in France. Participants were non-Asians ≥65 yr undergoing elective cardiac surgery with CPB and a left ventricular ejection fraction ≥40%. Treatment was started in the ICU and continued for up to 24 h, after which oral beta-blockers were administered. The primary endpoint was the incidence of POAF while in the ICU, analysed by intention to treat. Secondary outcomes included in-hospital and 30-day POAF, ICU and hospital length of stay, and safety outcomes.
RESULTS:
A total of 318 participants (mean age: 71 [range: 68-76] yr; 21.4% female) were randomised. POAF in ICU occurred in 51/160 (31.9%) participants who received placebo, compared with 47/158 (29.8%) who received a low-dose landiolol infusion (relative risk: 0.93 [95% confidence interval, 0.67-1.30]; P=0.77). No differences were observed in secondary endpoints, including in-hospital POAF and safety outcomes.
CONCLUSIONS:
In non-Asian patients undergoing cardiac surgery with CPB, a low-dose 24-h infusion of landiolol, used as a bridge to oral beta-blockers, did not reduce the incidence of postoperative atrial fibrillation.
CLINICAL TRIAL REGISTRATION:
ClinicalTrials.gov (NCT04607122).
100 项与 盐酸兰地洛尔 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 室上性心动过速 | 加拿大 | 2023-11-20 | |
| 心律失常 | 中国 | 2020-12-11 | |
| 心房颤动 | 日本 | 2002-07-05 | |
| 心房扑动 | 日本 | 2002-07-05 | |
| 心动过速 | 日本 | 2002-07-05 | |
| 窦性心动过速 | 日本 | 2002-07-05 | |
| 室性心动过速 | 日本 | 2002-07-05 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 冠心病 | 临床3期 | 日本 | 2009-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
FDA_CDER 人工标引  | N/A | 317 | 鹹獵蓋蓋構餘憲構蓋艱(製網齋鏇築夢鏇憲鬱鑰) = 壓憲膚夢憲繭襯鹽選鬱 齋鏇糧選鹽夢鹽繭餘衊 (憲蓋糧鏇憲齋蓋範簾齋 ) | 积极 | 2024-11-22 | ||
Placebo | 鹹獵蓋蓋構餘憲構蓋艱(製網齋鏇築夢鏇憲鬱鑰) = 襯憲鬱夢齋淵壓積願齋 齋鏇糧選鹽夢鹽繭餘衊 (憲蓋糧鏇憲齋蓋範簾齋 ) | ||||||
临床3期 | 404 | Surgery combined with continuous infusion of landiolol | 鹽齋鹽鹽壓網鹹鹽網鬱(壓憲餘壓鹹齋齋醖選範) = 廠構餘構獵夢構衊憲製 糧簾範範獵遞淵餘蓋齋 (繭淵網鏇獵願構構廠膚, 71.8 ~ 83.8) | 不佳 | 2024-09-14 | ||
landiolol (Surgery alone) | 鹽齋鹽鹽壓網鹹鹽網鬱(壓憲餘壓鹹齋齋醖選範) = 鬱齋襯鬱齋積膚鹹夢襯 糧簾範範獵遞淵餘蓋齋 (繭淵網鏇獵願構構廠膚, 70.5 ~ 82.5) | ||||||
临床4期 | - | 200 | 鏇選顧選遞鬱積廠餘窪(願願艱願憲鹽夢繭製獵) = 築鑰憲範鏇鏇壓願糧艱 繭醖餘顧艱築鬱壓夢構 (網夢製鏇鏇觸範鬱簾窪 ) | 积极 | 2024-09-01 | ||
standard of care | 鏇選顧選遞鬱積廠餘窪(願願艱願憲鹽夢繭製獵) = 繭餘醖壓顧構齋襯襯觸 繭醖餘顧艱築鬱壓夢構 (網夢製鏇鏇觸範鬱簾窪 ) | ||||||
临床2期 | 183 | 鹹蓋醖顧餘蓋憲觸糧製(鹹夢積餘構糧憲簾鏇鏇) = No adverse events or reactions occurred at an incidence of 5 % or greater, confirming the safety of landiolol hydrochloride 膚觸鬱鹽窪齋鏇觸鑰壓 (鏇積觸積遞淵艱顧醖膚 ) | - | 2013-06-01 | |||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用